Company intelligence / Profile preview
SynerGene Therapeutics, Inc.
Potomac, Maryland, United Statessynergenetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple clinical trials including a Phase 2 study of SGT-53 plus gemcitabine/nab-paclitaxel for metastatic pancreatic cancer, and an early Phase 1 study of SGT-53 with irradiation and chemotherapy in children with recurrent CNS malignancies. Their technology delivers therapeutic genes specifically to targeted disease sites while avoiding healthy cells.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Gene therapyNanocomplex delivery systemsPlasmid DNAsiRNA/miRNAAS ODNSmall moleculesChemotherapy drugsImaging agents
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on SynerGene Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynerGene Therapeutics, Inc..